PLEASANTON, California, Jan. 14, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the company has entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway (including in the KRAS gene). Financial details were not disclosed.
The licenses apply to testing products which detect these mutations using molecular techniques including PCR, next generation sequencing (NGS) and other applications to aid in identification of cancer patients eligible for treatment with certain tyrosine kinase inhibitors. The licenses can be applied to existing and future products.
"As a leader in molecular assay development, we are pleased to provide licenses to the applicable patents so that existing and new tests can support patient treatment decisions," said Paul Brown, Head of Roche Molecular Diagnostics. "Ensuring that assays that utilize Roche proprietary information are fully licensed is a key business strategy for us."
"We are pleased with the agreement, which expands our existing intellectual property portfolio covering more than 35 biomarkers and our deep intellectual property estate in EGFR-related testing, including KRAS- testing," said Dr. Achim Ribbe, Vice President Corporate Business Development Licensing. "As a global leader in personalized healthcare, QIAGEN is working with numerous pharmaceutical companies to develop and market molecular companion diagnostics that can help improve patient outcomes and better utilize healthcare resources."
About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For media inquiries please contact: Bob Purcell, Roche Molecular Diagnostics 888-545-2443
Claudia Panozzo, Austria+43 1 277 87 360
Silvia Zucca, Italy+39 039 2817 612
Francisco Aguilar-Alvarez, Spain+34 93583 4011
Eudes de Villiers, France+33 4 76 76 31 26
Banu Kutlu, Turkey00902123060606
Harald Borrmann, Switzerland+41 41 799 6253
Kate Hoile, UK+44 1444 256591
Jan Schreiber, Germany+49 621 759 5156
Mike Weist, US+1 317 521 3112